Scaling for Growth: Building a Foundation for Your Company’s Next Inflexion Point
By Sandra Gardiner
My career as a finance executive in both biotech and medtech Life Sciences companies has included many assignments where growth was imperative, despite prevailing countercurrents in the market and the challenges this imposed internally: At Lipid Sciences, a privately held biotechnology company pursuing HDL therapies for cardiac and viral applications,…Read More
Read More2024 Trends & FLG Partners Celebrates 20 Years of Success
By Laureen DeBuono
In 2024, FLG Partners will celebrate our 20th Anniversary in business, thanks to the hundreds of clients, referral partners and industry colleagues who have helped us meet our objectives. Because of partnering with these colleagues, we have been able to close: 350+ M&A transactions 200+ IPOs 100+ Divestiture transactions And…Read More
Read MoreThe Startup’s Dilemma: Planning for Success vs. Conserving Cash
By Andrew Levitch
Having spent the past 12 years as a Life Sciences and Technology CFO consulting to venture and private-equity backed companies, I have seen a consistent and recurring dilemma faced by these emerging companies: the struggle between planning for success and conserving cash. The age-old adage “you have to spend money…Read More
Read MoreIs Now a Good Time to Be Planning For An IPO?
By Nancy Hargreaves
As we zero-in on year-end 2023, the IPO market appears to be opening up a little. While there is cautious optimism around this emerging trend, it’s clear that the volume of transactions and valuations seen in 2020 and 2021 are unlikely to be seen again any time soon. Today, pent-up…Read More
Read More